Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × ixazomib × Clear all

Phase

Status

Completed 2 Withdrawn 1 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 10 Neoplasms, Plasma Cell 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoglobulin Light-chain Amyloidosis 1 Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 18 Dexamethasone 15 fludarabine 11 Rituximab 7 pomalidomide 6 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 carfilzomib 6 venetoclax 5 Lenalidomide 5 Gemcitabine 5 Cisplatin 5 Calcium Dobesilate 5 Nivolumab 4 Etoposide 4 Bortezomib 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cabazitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03651128 2022-12-15

KarMMa-3

Celgene

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡